| |
| |
|
| Insider
Information: |
Gryska David W |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
174,851 |
|
|
Indirect Shares
|
750 |
|
|
| Direct
Value |
$984,634 |
|
|
|
Indirect Value
|
$81,180 |
|
|
| Total
Shares |
175,601 |
|
|
| Total
Value |
$1,065,814 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
8
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 15.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Seagen Inc |
SGEN |
|
2023-12-14 |
0 |
2006-02-14 |
0 |
Premium* |
|
|
Celgene Corp |
CELG |
Chief Financial Officer |
2010-05-04 |
864 |
2010-05-04 |
750 |
Premium* |
|
|
PDL Biopharma Inc |
PDLI |
Director |
2020-12-30 |
1,387 |
2014-03-06 |
0 |
Premium* |
|
|
Incyte Corp |
INCY |
Executive Vice Preside... |
2018-07-16 |
10,235 |
2015-01-08 |
0 |
Premium* |
|
|
Aerie Pharmaceuticals Inc |
AERI |
Director |
2022-11-21 |
0 |
2022-11-21 |
0 |
Premium* |
|
|
Mind Medicine |
MNMD |
Director |
2023-06-21 |
13,851 |
2023-06-21 |
0 |
Premium* |
|
|
Forte Biosciences Inc |
FBRX |
Director |
2023-07-31 |
148,514 |
2023-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FBRX |
Forte Biosciences Inc |
Director |
– • – |
2023-07-31 |
4 |
A |
$1.01 |
$149,999 |
D/D |
148,514 |
148,514 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-11-17 |
4 |
S |
$2.40 |
$240,000 |
D/D |
(100,000) |
145,337 |
0 |
% |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-12-03 |
4 |
S |
$2.52 |
$189,000 |
D/D |
(75,000) |
30,337 |
0 |
% |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-12-16 |
4 |
S |
$2.68 |
$201,000 |
D/D |
(75,000) |
21,387 |
0 |
% |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2016-06-02 |
4 |
A |
$3.52 |
$250,001 |
D/D |
71,023 |
104,434 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-12-05 |
4 |
OE |
$1.64 |
$108,322 |
D/D |
66,050 |
96,387 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2017-06-09 |
4 |
A |
$2.47 |
$150,001 |
D/D |
60,729 |
165,163 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-11-18 |
4 |
OE |
$1.64 |
$98,400 |
D/D |
60,000 |
155,337 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2018-06-08 |
4 |
A |
$2.76 |
$150,000 |
D/D |
54,348 |
219,511 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-11-18 |
4 |
S |
$2.39 |
$119,500 |
D/D |
(50,000) |
95,337 |
0 |
% |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-11-23 |
4 |
S |
$2.43 |
$121,500 |
D/D |
(50,000) |
105,337 |
0 |
- |
|
| SGEN |
Seagen Inc |
|
– • – |
2023-12-14 |
4 |
D |
$229.00 |
$11,221,687 |
D/D |
(49,003) |
0 |
0 |
- |
|
| INCY |
Incyte Corp |
Executive Vice President, CFO |
• – – |
2017-04-10 |
4 |
AS |
$138.00 |
$5,730,864 |
D/D |
(41,528) |
19,015 |
0 |
- |
|
| INCY |
Incyte Corp |
Executive Vice President, CFO |
• – – |
2017-04-10 |
4 |
OE |
$67.06 |
$2,784,868 |
D/D |
41,528 |
60,543 |
0 |
- |
|
| CELG |
Celgene Corp |
Chief Financial Officer |
• – – |
2010-05-03 |
4 |
OE |
$49.61 |
$1,653,025 |
D/D |
32,499 |
7,499 |
0 |
- |
|
| CELG |
Celgene Corp |
Chief Financial Officer |
• – – |
2010-05-03 |
4 |
S |
$61.63 |
$2,003,073 |
D/D |
(32,499) |
0 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
25,826 |
245,337 |
0 |
- |
|
| CELG |
Celgene Corp |
Chief Financial Officer |
• – – |
2008-11-03 |
4 |
S |
$64.50 |
$1,500,528 |
D/D |
(23,264) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
Chief Financial Officer |
• – – |
2008-11-03 |
4 |
OE |
$57.58 |
$1,339,541 |
D/D |
23,264 |
23,264 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2015-05-28 |
4 |
A |
$6.80 |
$150,001 |
D/D |
22,059 |
33,411 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2020-12-30 |
4 |
S |
$2.74 |
$54,800 |
D/D |
(20,000) |
1,387 |
0 |
- |
|
| INCY |
Incyte Corp |
Executive Vice President, CFO |
• – – |
2017-06-12 |
4 |
OE |
$73.21 |
$1,226,707 |
D/D |
16,756 |
35,771 |
0 |
- |
|
| INCY |
Incyte Corp |
Executive Vice President, CFO |
• – – |
2017-06-12 |
4 |
AS |
$116.60 |
$1,953,750 |
D/D |
(16,756) |
19,015 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2020-11-19 |
4 |
S |
$173.25 |
$2,605,523 |
D/D |
(15,000) |
44,848 |
0 |
% |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2020-11-19 |
4 |
OE |
$19.02 |
$285,300 |
D/D |
15,000 |
52,719 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
